It has been proposed that weight loss associated with GLP-1 agonist use may lead to better detection of breast lumps but evidence to support this association of weight loss and detection is lacking. The researchers also note that findings from the largest randomised trial of liraglutide the LEADER trial [3] , published in June 2016 did not indicate an elevated risk of breast cancer associated with the drug
At ATX Infusion and Wellness, we offer personalized care grounded in science and safety
If you develop a fever or feel unwell, seek medical attention promptly
The 3 mg dose is for initiation only
What happens if you stop sermorelin but continue semaglutide? You lose the lean mass preservation benefit, but semaglutides appetite suppression and weight loss continue unchanged
Advisory Board fees from Sanofi-Aventis, Astra Zeneca, Novo Nordisk, Eli Lilly, and Novartis